Medtronic has announced the commercial launch of the OmniaSecure defibrillation lead in the U.S., with first cases being performed at hospitals across the country.
The world’s smallest-defibrillation lead — approved for adults and the first for pediatric patients ages 12 and up — connects to an implantable defibrillator to treat potentially life-threatening heart rhythm issues like ventricular tachyarrhythmias, ventricular fibrillation (VT/VF) and bradyarrhythmias.
Implantable cardioverter defibrillators (ICDs) are the standard for preventing sudden cardiac death, and existing defibrillation leads are larger in diameter than the OmniaSecure lead. A larger-diameter lead may increase the potential for downstream complications, such as venous occlusion or tricuspid valve regurgitation.
The lead was engineered from the proven Medtronic SelectSecure Model 3830 pacing lead, which has delivered safe and reliable therapy to patients for more than 20 years.
Prior to commercial launch, the final results from the LEADR (Lead Evaluation for Defibrillation and Reliability) Pivotal Trial were presented at APHRS and reaffirmed the lead’s established performance and reliability with high defibrillation success and low lead-related major complications.
July 28, 2023 
